Cancer Diagnosis Segment by Application to Account Larger Share in Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market during 2022–2030

According to our latest study on “US Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market Size and Forecasts (2020 - 2030), Country Share, Trends, and Growth Opportunity Analysis" the market is expected to grow from US$ 419.74 million in 2022 and is expected to reach US$ 733.71 million by 2030; it is anticipated to record a CAGR of 7.2% from 2022 to 2030. The report highlights the key factors driving the growth of fluorescence in-situ hybridization (FISH) imaging systems and prominent players with their developments in the market.

Fluorescence in situ hybridization (FISH) is a molecular technique for cytogenetic analysis. This technique uses fluorescent probes that bind to only particular parts of a nucleic acid sequence with a high degree of sequence complementarity. FISH detects the presence or absence of specific DNA sequences on chromosomes. FISH is often used to find specific features in DNA/RNA targets for medicine, genetic counseling, and species identification.

The fluorescence in-situ hybridization (FISH) imaging systems market, by product, is segmented into instruments, consumables, accessories, and software. The consumables segment held a larger market share in 2022 and the same segment is anticipated to register a higher CAGR. Based on application, the fluorescence in-situ hybridization (FISH) imaging systems market is segmented into cancer diagnosis, genetic disease diagnosis, infectious disease diagnosis, and others. The cancer diagnosis segment held a larger market share in 2022. FISH technology has tremendously benefited cancer diagnosis. FISH imaging systems can look for gene changes and help detect anomalies. According to Cancer Research UK, FISH testing is used for the diagnosis of several cancers, including breast cancer, lymphoma, lung cancer, prostate cancer, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myeloma, Ewings sarcoma, and melanoma skin cancer. Based on end user, the fluorescence in-situ hybridization (FISH) imaging systems market is segmented into diagnostic laboratories, contract research organization, pharmaceutical and biotechnological companies, and others. The diagnostic laboratories segment held a larger market share in 2022 and same segment is anticipated to register a higher CAGR.

Euroclone SpA, TissueGnostics GmbH, Agilent Technologies Inc, Abnova Taiwan Corp, BioGenex Laboratories Inc, Leica Biosystems Nussloch GmbH, MetaSystems Probes GmbH, Bio-View Ltd, Thermo Fisher Scientific Inc, Applied Spectral Imaging, and PerkinElmer Inc are among the leading companies operating in the global Fluorescence In-Situ Hybridization (FISH) Imaging Systems market.    

Companies operating in the fluorescence in-situ hybridization (FISH) imaging systems market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the fluorescence in-situ hybridization (FISH) imaging systems market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall fluorescence in-situ hybridization (FISH) imaging systems market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the significant developments by key market players are listed below.

• In May 2023, Pfizer and Thermo Fisher Scientific Inc entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in over 30 countries across Latin America, Africa, the Middle East, and Asia where advanced genomic testing was previously limited or unavailable. Access to local NGS testing can help enable faster analysis of related genes, allowing healthcare providers to choose the best medicine for that specific patient.
• In April 2023, Agilent Technologies Inc had signed a memorandum of understanding with Theragen Bio in South Korea. As part of the partnership agreement, Agilent and Theragen Bio combined their respective strengths in cancer genomic profiling design, engineering knowledge and software expertise to drive localized analysis capabilities and accelerate treatment decisions.
• In December 2021, BioGenex Laboratories Inc had launched three new primary immunohistochemistry (IHC) antibodies for cancer diagnostics, which includes CD8A, CD56, and CD163.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com